智通财经APP获悉，瑞博生物-B(06938)涨超9%，截至发稿，涨8.9%，报58.15港元，成交额3203.51万港元。
消息面上，恒生指数公司于8月21日公布了半年度指数调整结果，其中瑞博生物获纳入恒生综合指数。变动将于9月4日收市后实施并于9月7日起生效，届时沪深交易所会相应调整港股通可投资标的范围。本次纳入恒生综合指数后，公司股票预计将同步符合港股通可投资标的资格。
瑞博生物此前预期今年上半年取得收入约3.11亿-4.36亿元，同比增长约200%至320%，主要是由于部分确认集团与Madrigal Pharmaceuticals, Inc全球独家许可合作项下的许可收入，连同集团与勃林格殷格翰国际公司合作达致里程碑时确认的收入。上述合作均涉及用于代谢功能障碍相关脂肪性肝炎(MASH)的小干扰RNA(siRNA)疗法的开发及商业化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.